Home » Stocks » RPTX

Repare Therapeutics, Inc. (RPTX)

Stock Price: $41.50 USD -2.54 (-5.77%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $40.00 -1.50 (-3.61%) Jan 15, 4:19 PM
Market Cap 1.53B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 36.76M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $41.50
Previous Close $44.04
Change ($) -2.54
Change (%) -5.77%
Day's Open 43.10
Day's Range 40.00 - 45.30
Day's Volume 124,653
52-Week Range 21.55 - 45.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprieta...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its pr...

Seeking Alpha - 3 weeks ago

Synthetic Lethality (SL) is a promising approach for cancer treatments. Repare's SNIPRx platform has the potential to identify SL pairs to create new therapies.

Business Wire - 1 month ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprieta...

Business Wire - 1 month ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar...

Zacks Investment Research - 2 months ago

Repare Therapeutics (RPTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 4 months ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

Benzinga - 6 months ago

Repare Therapeutics Inc. (NASDAQ: RPTX), which is working to develop precision oncology therapies by leveraging synthetic lethal interactions in cancer, went public in June.

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RNA, XBI, ZNTL
Business Wire - 6 months ago

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the disco...

GuruFocus - 6 months ago

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

Other stocks mentioned: FMTX

About RPTX

Repare Therapeutics, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developin... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
CEO
Lloyd Mitchell Segal
Employees
79
Stock Exchange
NASDAQ
Ticker Symbol
RPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is 40.00, which is a decrease of -3.61% from the latest price.

Price Target
$40.00
(-3.61% downside)
Analyst Consensus: Buy